Clinical trials: Degenerative Conditions, Neurologic
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Alzheimer's Disease, Vascular Dementia
BAC in Patient With Alzheimer's Disease or Vascular Dementia
The primary objective of this study is to evaluate the efficacy of BAC patients with Alzheimer's disease or vascular dementia.The secondary objective of this study is to evaluate the safety of BAC patients with Alzheimer's…
- Trial name
- NCT02467413
- Testing
- BAC, BAC Matched Vehicle
- Where
- Taiwan
- Sponsor
- Botanicure Co., Ltd.
Alzheimer Disease
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared…
- Trial name
- NCT01680588
- Testing
- [18F]NAV4694
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Amyotrophic Lateral Sclerosis, Fasciculation
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
The FLX-787-107 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03334786
- Testing
- FLX-787-ODT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Flex Pharma, Inc.
Spinocerebellar Degeneration
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients
- Trial name
- NCT01970124
- Testing
- KPS-0373, High dose, KPS-0373, Low dose
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Amyloidosis
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT02510261
- Testing
- Patisiran
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 211 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer's Disease
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00809510
- Testing
- ABT-089
- Where
- 22 sites in United States
- Volunteers
- 63 people
- Sponsor
- Abbott
Alzheimer Disease
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
- Trial name
- NCT00141661
- Testing
- PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Alzheimer's Disease
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with…
- Trial name
- NCT02580305
- Testing
- SUVN-502, Donepezil, Memantine
- Where
- 71 sites in United States
- Volunteers
- 564 people
- Sponsor
- Suven Life Sciences Limited
Alzheimer Disease, Down Syndrome
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
- Trial name
- NCT06673069
- Testing
- ION269
- Where
- 6 sites in United States, Spain
- Volunteers
- 1 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cerebral Palsy, Acquired Brain Injury
Safety and Usability of a Robotic Gait Device for Children and Adolescents With Neurological or Neuromuscular Disease in Their Natural Environment
The goal of this clinical trial is to analyze the usability and safety of the robotic gait device EXPLORER in children with cerebral palsy, acquired brain injury and spinal muscular atrophy.
- Conditions
- Cerebral Palsy, Acquired Brain Injury, Spinal Muscular Atrophy
- Trial name
- NCT06167954
- Testing
- EXPLORER
- Where
- 5 sites in Spain
- Volunteers
- 50 people
- Sponsor
- MarsiBionics
Leber's Hereditary Optic Neuropathy (LHON)
Post Authorisation Safety Study With Raxone in LHON Patients
This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study.
- Trial name
- PAROS (NCT02771379)
- Testing
- Idebenone
- Where
- 26 sites in Austria, France and 4 more
- Volunteers
- 229 people
- Sponsor
- Santhera Pharmaceuticals
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
- Trial name
- SP715 (NCT00594386)
- Testing
- Rotigotine
- Where
- 41 sites in United States, Canada
- Volunteers
- 258 people
- Sponsor
- UCB Pharma
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
- Trial name
- TARBELA-AD (NCT07781657)
- Testing
- RO7568282
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Single Ascending Dose Study of PRX002 in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Trial name
- NCT02095171
- Testing
- PRX002
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prothena Biosciences Limited
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.